Maegim한국어

하이텍팜

106190KOSDAQSector: Pharma & Biotech
₩10,340▼ 1.62%Market cap ₩109.9BAs of Jul 21, 2026 close · updated once daily
A
Grade A70.6 ptsTop 10% of 2,523 stocks
Financial strength
84.6
Growth momentum
39.2
Price attractiveness
77.1

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

84.6
How much debt does it carry relative to equity?
Debt-to-equity ratio
10.0%
✓ Above median · Top 12.4% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
567.1%
✓ Above median · Top 23.8% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
18.3%
✓ Above median · Top 8.4% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
8.8%
✓ Above median · Top 16.9% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

39.2
How much did revenue grow in a year?
Revenue growth (YoY)
-9.5%
✗ Below median · Top 79.7% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
-12.0%
✗ Below median · Top 85.4% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-17.4%
✗ Below median · Top 69.4% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
160.9%
✓ Above median · Top 8.9% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

77.1
Is the price expensive relative to earnings?
P/E (price-to-earnings)
9.6x
✓ Above median · Top 13.2% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.84x
✓ Above median · Top 32.7% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15